Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
European Journal of Haematology|April 2, 2015
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessmentMoshe E Gatt, Izhar Hardan, Evgeni Chubar, et al.
Haematologica|October 6, 2022
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trialNathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL AmyloidosisShlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, et al.
Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.
British Journal of Haematology|May 8, 2013
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activityMoshe E Gatt, Kohichi Takada, Mala Mani, et al.
Cancer Research|September 10, 2009
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cellsMala Mani, Daniel E Carrasco, Yunyu Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2024
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 StudyAlbert Oriol, Roman Hájek, Ivan Spicka, et al.
Leukemia Research|January 16, 2021
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre studyTamir Shragai, Moshe E Gatt, Adir Shaulov, et al.
Leukemia & Lymphoma|September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study GroupChezi Ganzel, Svetlana Trestman, Shai Levi, et al.
Cancers|July 14, 2023
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?Vladimir Vainstein, Batia Avni, Sigal Grisariu, et al.
Pageof 9